The primary objective of this study is to evaluate the efficacy of inhaled nebulized AIR001 administered for 16 weeks.

This is a phase III/IV, double-blinded study to compare two treatment strategies; first line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with PAH. This will be assessed to the first clinical failure event.

The goal of CoPARC is to develop a readily accessible biorepository of data and clinical samples from subjects with alcohol abuse and dependence as well as healthy controls. While our primary focus is on alcohol-related pulmonary processes, we hope to extend our resources to support research on alcohol’s effects on conditions that lead to critical illness.

This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

The purpose of this study is to establish a biorepository of biological samples and genetic data of patient with WHO group 1 PAH. Once established the function of the biorepository is to collect the samples from the patients, generate the proposed genetic data, and widely promote and distribute the samples/data to the scientific community. No hypothesis driven science is proposed for this project.

A Double-Blind, Placebo-Controlled Study to Compare Subjects with PAH Receiving UT-15C in Combination with a PDE5-I or ERA Compared with PDE5-I or ERA Alone.